Forge Biologics Unveils FUEL™ Platform, Revolutionizing AAV Gene Therapy Production with 6x Productivity Boost

October 3, 2024
Forge Biologics Unveils FUEL™ Platform, Revolutionizing AAV Gene Therapy Production with 6x Productivity Boost
  • Forge Biologics has introduced its FUEL™ manufacturing platform, aimed at significantly enhancing the efficiency of AAV gene therapy production.

  • This innovative platform can boost productivity by 2 to 6 times compared to current industry standards for AAV gene therapies.

  • The FUEL™ platform integrates advanced technologies, including the pEMBR 2.0™ Ad helper plasmid and modified rep/cap plasmids, to optimize production processes.

  • Notably, the pEMBR 2.0™ Ad helper is one of the smallest commercially available at 8.9kb, which contributes to improved safety and manufacturing efficiency.

  • A critical component of the FUEL™ platform is Forge’s HEK293 suspension Ignition™ cell line, which enhances the speed and safety of AAV production.

  • John Maslowski, President & CEO of Forge, highlighted the platform's role in supporting clients throughout the development process, from discovery to clinical trials.

  • David Dismuke, Ph.D., Chief Technical Officer of Forge, praised the collaborative efforts of the team that led to the productivity gains achieved with the FUEL™ platform.

  • Data regarding the FUEL™ platform will be showcased at the upcoming Cell & Gene Meeting on the Mesa.

  • Maslowski is set to present the FUEL™ platform at the Alliance for Regenerative Medicine’s event on October 8, 2024, in Phoenix, Arizona.

  • Forge Biologics is based in Columbus, Ohio, and operates a 200,000 square foot facility specifically designed for scalable gene therapy manufacturing.

  • The platform's new modified rep/cap plasmids allow for the integration of client-specific capsid sequences into the proprietary backbone plasmid.

Summary based on 2 sources


Get a daily email with more Gene Therapy stories

More Stories